CA
NZ
UK
AU
IND
US
ZipRecruiter reported $118.1 million in revenue for Q2 2026, a 5% year-over-year increase, beating the consensus estimate of $112.1 million. The company's strong performance is attributed to its differentiated approach and product improvements, which have increased conversations between employers and job seekers.Key HighlightsThe company's …
Dermata Therapeutics, Inc. is set to launch its first commercial product, the Foundational Treatment, priced at $178, starting August 25, 2026. This announcement marks a significant milestone in the company's transition to bringing consumer products to market. The Foundational Treatment package includes four once-weekly …
Akebia Therapeutics, Inc. (NASDAQ: AKBA) reported a second-quarter net loss of $8.9 million on total revenues of $49.1 million, down from $62.5 million a year prior. The company's performance reflects challenges, primarily due to reduced revenues from Auryxia, even as Vafseo sales showed significant …
Pinterest's Q2 earnings report has failed to impress investors, with the stock falling 8% after hours despite a beat on earnings. The company's revenue also beat expectations, but the outlook for the rest of the year has disappointed investors. This has led to a …
Arcus Biosciences, Inc. (NYSE: RCUS) achieved an EPS of $-0.72 for the quarter ending June 30, 2026, exceeding analysts' expectations who had predicted a loss of $-0.92. This marks a favorable shift, as the performance demonstrates the company’s commitment to establishing casdatifan as a …
Arcutis Biotherapeutics (NASDAQ: ARQT) reported net product revenue of $129.9 million for the second quarter, a 59% year‑over‑year climb and a 23% sequential jump, while earnings per share reached $0.11 against a $0.04 consensus. The earnings surprise and strong sales lift the company’s cash‑flow …
Bank of America Corp. is investing $250 million annually in GLP-1 weight-loss drugs, a move aimed at enhancing employee health and productivity. This figure underscores the company's commitment to addressing rising healthcare costs associated with obesity-related conditions. The decision reflects a growing trend among …
BeOne Medicines Ltd. reported second quarter revenues of $1.7 billion, a strong increase of 30% compared to the same period last year. This growth was largely propelled by the impressive performance of its leading product, BRUKINSA, which accounted for $1.2 billion in sales, up …
BillionToOne (NASDAQ: BLLN) posted second‑quarter revenue of $109.4 million, a 64% year‑over‑year increase, while earnings per share slipped to $0.15 against a $0.19 consensus estimate. The surge was powered by a $94.2 million boost in prenatal testing and a $13.7 million surge in oncology …
Sandisk Corp. reported earnings per share of $39.25 for the quarter ended June 30, 2026, surpassing analyst expectations of $35.14. However, the midpoint of its revenue guidance fell below market forecasts, leading to a 9.1% drop in shares to $1,227.12 in pre-market trading. This …
Please wait processing your request...